Kura Oncology, Inc. (KUR.F)
Frankfurt · EUR · Healthcare · Biotechnology
€8.44 (-0.24%) as of
Key statistics
- Market cap
- 750.83M
- Forward P/E
- -3.62
- EPS (TTM)
- -2.89
- Dividend yield
- 0.00%
- 52-week range
- 6.15 – 11.80
- Beta
- 0.47
- Revenue (TTM)
- 77.22M
- Profit margin
- 0.00%
- Volume
- 1.82k
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- San Diego, CA, United States
- Employees
- 260
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.